Some artificial sweeteners can change the composition of the gut microbiome, which impacts health more broadly
Ian Allenden/Alamy
Research suggests that consuming the artificial sweetener sucralose may hinder the effectiveness of cancer immunotherapy, a treatment that harnesses the immune system to fight cancer cells.
Immunotherapy has shown remarkable success in treating various cancers, but its effectiveness varies among patients. Scientists at the University of Pittsburgh have found a potential link between artificial sweeteners and immunotherapy outcomes, highlighting the importance of diet in cancer treatment.
Studies have indicated that the gut microbiome, which plays a crucial role in regulating immune responses, can be influenced by artificial sweeteners. By analyzing data from 157 individuals undergoing cancer immunotherapy, researchers discovered that higher consumption of sucralose was associated with poorer treatment outcomes.
Participants with advanced melanoma and non-small cell lung cancer who consumed more sucralose had shorter progression-free survival compared to those with lower consumption. Similarly, individuals at high risk of melanoma recurrence showed a significant difference in cancer-free survival based on sucralose intake.
Furthermore, the study revealed that another artificial sweetener, acesulfame K, also had a negative impact on immunotherapy outcomes when consumed in high quantities. These findings raise concerns about the recommended daily intake of artificial sweeteners set by regulatory bodies.
Experiments conducted on mice with cancer further supported the link between sucralose and impaired immunotherapy. Mice exposed to sucralose during treatment showed increased tumor growth and reduced survival rates, indicating a direct effect on the immune response.
Analysis of T-cells, essential immune cells for fighting cancer, in sucralose-exposed mice revealed impaired function, potentially due to alterations in the gut microbiome. Supplementing the mice with arginine, an amino acid crucial for T-cell function, improved their survival rates, suggesting a possible intervention for mitigating the negative effects of artificial sweeteners.
While the study provides valuable insights into the impact of sucralose on cancer treatment, further research is needed to determine the exact mechanisms at play in humans. Scientists emphasize the importance of considering dietary factors in treatment efficacy and advocate for more studies to explore the relationship between artificial sweeteners and immunotherapy outcomes.
Ultimately, the findings suggest that simple changes in diet, such as avoiding artificial sweeteners or incorporating specific supplements, could enhance the effectiveness of existing cancer treatments. By prioritizing research in this area, healthcare professionals aim to optimize patient outcomes and improve the quality of cancer care.
Topics:
